Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  eribulin mesylate
Find trials that include:  Any drugs shown
Results 1-21 of 21 for your search:
Start Over
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: E7389-A001-303, NCI-2014-01285, NCI-2014-00255, RU011201I, NCT02037529
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CP-MGAH22-04, NCI-2016-00295, NCT02492711
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-119, NCI-2016-00327, 153082, 2015-001020-27, NCT02555657
Eribulin Mesylate and Cyclophosphamide in Treating Patients With Solid Tumor Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: 11996, NCI-2012-00436, NCT01554371
Multitargeted Tyrosine Kinase Inhibitor PLX3397 and Eribulin Mesylate in Treating Patients with Triple-Negative Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12751, NCI-2015-01321, 141658, CC#12751, NCT01596751
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: E7389-M001-218, NCI-2015-01436, KEYNOTE-150, NCT02513472
Eribulin Mesylate in Treating Patients with Advanced or Recurrent Cervical Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 5C-11-2, NCI-2012-01378, HS-11-00547, NCT01676818
Eribulin Mesylate in Treating Patients with HER2-Negative Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-077, NCI-2013-01115, NCT01827787
Eribulin Mesylate in Treating Patients with Previously Treated Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8093, NCI-2013-01326, NCT01908101
Eribulin Mesylate, Trastuzumab, and Pertuzumab in Treating Patients with HER2-Positive Breast Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-163, NCI-2013-01826, 688097, 707389, NCT01912963
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients with Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9653, NCI-2014-01294, P9653_A02PAMDREVW01, PHII-130, NCT02178241
Eribulin Mesylate in Treating Patients with Brain Metastases from Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CASE 7113, NCI-2015-01792, NCT02581839
Eribulin Mesylate and Lenvatinib Mesylate in Treating Patients with Stage IV Breast Cancer, Non-Small Cell Lung Cancer, or Sarcoma
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CTMS 15-2139, NCI-2016-00344, HSC20150891H, NCT02640508
Eribulin Mesylate Followed by Doxorubicin Hydrochloride and Cyclophosphamide in Treating Patients with HER2-negative Inflammatory Breast Cancer before Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-292, NCI-2016-00329, NCT02623972
Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 55
Trial IDs: POL-7, NCI-2014-01233, NCT01837095
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: C1073-500, NCI-2015-00521, NCT02014337
Eribulin Mesylate and Everolimus in Treating Patients with Triple-Negative Metastatic Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14036, NCI-2014-00844, 112905, 117995, 119537, 120213, NCT02120469
Eribulin Mesylate in Treating Younger Patients with Refractory or Recurrent Solid Tumors or Lymphomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 17 years
Trial IDs: ADVL1314, NCI-2014-00714, NCT02171260
Eribulin Mesylate and Irinotecan Hydrochloride in Treating Adolescent and Young Adult Patients with Relapsed or Refractory Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 to 39
Trial IDs: ERIB-IRINO-SLDTMR, NCI-2016-00347, NCT02318589
Selinexor with Multiple Standard Chemotherapy Regimens in Treating Patients with Advanced Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0640, NCI-2015-00693, NCT02419495
Neuropharmacokinetics of Eribulin Mesylate in Treating Patients with Brain Metastases from Breast, Bladder, or Non-small Cell Lung Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14312, NCI-2014-02391, 113114, 120431, NCT02338037
Start Over